ライフサイエンスコーパス: corticotropin-releasing factor

1 ORs that colocalize with the stress hormone, corticotropin releasing factor.

2 e diuretic hormone 44 (DH44), an ortholog of corticotropin-releasing factor.

3 he transmembrane domains of the glucagon and corticotropin releasing factor 1 (CRF1) receptors to dev

4 An orally active clinical candidate of corticotropin-releasing factor 1 (CRF 1) antagonist 1 sh

5 ective, and orally active antagonists of the corticotropin-releasing factor 1 (CRF 1) receptor.

6 ist (eticlopride), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (anta

7 urthermore, pharmacologic inhibition (with a corticotropin-releasing factor 1 receptor antagonist) of

8 derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF(1)) receptor antag

9 s was identified as potent and orally active corticotropin-releasing factor-1 (CRF(1)) receptor antag

10 ctive withdrawal-like state characterized by corticotropin-releasing factor-1 (CRF(1)) receptor antag

11 Evidence suggests that corticotropin-releasing factor-1 (CRF(1)) receptor antag

12 ation of 8, an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF(1)) receptor antag

13 rmittent access to palatable food results in corticotropin-releasing factor-1 (CRF1) receptor antagon

14 ed by 8 were potent antagonists of the human corticotropin-releasing factor-1 receptor.

15 Corticotropin-releasing factor, a stress-related neurope

16 amine and opioid peptide function, increased corticotropin-releasing factor activity).

17 hine exposure sensitizes the LC-NE system to corticotropin releasing factor and stress.

18 t of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neu

19 alcohol drinking by increased expression of corticotropin-releasing factor and its feedback regulati

20 ween the N/OFQ and Hcrt systems in which the corticotropin-releasing factor and N/OFQ systems coordin

21 This parallels a similar effect of corticotropin-releasing factor and suggests a form of ne

22 by a variety of central (eg, neuropeptide Y, corticotropin-releasing factor, and neuromedin U) and pe

23 oactive intestinal polypeptide, substance P, corticotropin-releasing factor, and neuropeptide Y), ena

24 cial behavior (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol

25 Corticotropin releasing factor binding protein (CRF-BP)

26 Corticotropin releasing factor-binding protein (CRF-BP)

27 88-induced c-Fos activation were observed in corticotropin releasing factor-containing neurons of the

28 eus of the hypothalamus and primarily in non-corticotropin releasing factor-containing neurons of the

29 gh an interaction between the stress hormone corticotropin releasing factor (CRF) and glutamate relea

30 The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (

31 The circadian activity of corticotropin releasing factor (CRF) and the hypothalami

32 The corticotropin releasing factor (CRF) antagonist, alpha-h

33 blocked by intravenous pretreatment with the corticotropin releasing factor (CRF) antagonist, astress

34 Corticotropin releasing factor (CRF) coordinates the bra

35 The corticotropin releasing factor (CRF) family of ligands a

36 Here we demonstrate that, in the vBNST, corticotropin releasing factor (CRF) is expressed in neu

37 Corticotropin releasing factor (CRF) is the primary medi

38 Corticotropin releasing factor (CRF) is the primary regu

39 of this study was to examine the ability of corticotropin releasing factor (CRF) or antibody to insu

40 Corticotropin releasing factor (CRF) plays a major role

41 Reduced corticotropin releasing factor (CRF) receptor activity a

42 icotine withdrawal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expressi

43 e agonists and developed antagonists for the corticotropin releasing factor (CRF) receptors are new t

44 Corticotropin releasing factor (CRF) regulates physiolog

45 lar nucleus (PVN) have been shown to inhibit corticotropin releasing factor (CRF) synthesis via GABA(

46 The corticotropin releasing factor (CRF) system in the centr

47 The corticotropin releasing factor (CRF) system in the centr

48 The corticotropin releasing factor (CRF) type 1 receptor (CR

49 Corticotropin releasing factor (CRF) within the ventral

50 ontains a large number of neurons expressing corticotropin releasing factor (CRF), a neuropeptide tha

51 intracerebroventricular (icv) injections of corticotropin releasing factor (CRF), a putative anxioge

52 hanism underlying this response, we measured corticotropin releasing factor (CRF), an upstream modula

53 analyzed brain regional, CCK-8, substance P, corticotropin releasing factor (CRF), and neuropeptide Y

54 for 15 days and measured mRNA expression of corticotropin releasing factor (CRF), neuropeptide Y (NP

55 Urocortin 1 (Ucn 1) is an endogenous corticotropin releasing factor (CRF)-related peptide.

56 of action for the anxiogenic neuromodulator, corticotropin releasing factor (CRF).

57 ine seeking by the stress-sensitive peptide, corticotropin releasing factor (CRF).

58 presence of the prototypical stress hormone, corticotropin releasing factor (CRF).

59 The mammalian corticotropin releasing factor (CRF)/urocortin (Ucn) pep

60 Two new classes of tricyclic-based corticotropin-releasing factor (CRF(1)) receptor-1 antag

61 were measured at baseline and in response to corticotropin-releasing factor (CRF) (0.5 microg kg(1))

62 c raphe nucleus, including a coordination of corticotropin-releasing factor (CRF) actions at both of

63 We report that corticotropin-releasing factor (CRF) acts in the ventral

64 f chronic nicotine SA on the coexpression of corticotropin-releasing factor (CRF) and arginine vasopr

65 Although it has long been known that corticotropin-releasing factor (CRF) and CRF receptors a

66 ocus of the present review is on the role of corticotropin-releasing factor (CRF) and CRF-related pep

67 Long-term alterations in central corticotropin-releasing factor (CRF) and glucocorticoid

68 mRNA was found to partially colocalize with corticotropin-releasing factor (CRF) and growth hormone-

69 ajor site of extrahypothalamic expression of corticotropin-releasing factor (CRF) and its G-protein-c

70 Corticotropin-releasing factor (CRF) and its paralogues

71 Corticotropin-releasing factor (CRF) and nociceptin/orph

72 laced on the neuropharmacological actions of corticotropin-releasing factor (CRF) and norepinephrine

73 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the

74 Corticotropin-releasing factor (CRF) and related peptide

75 Corticotropin-releasing factor (CRF) and the closely rel

76 The stress-related neuropeptide corticotropin-releasing factor (CRF) and the serotonin s

77 Corticotropin-releasing factor (CRF) and urocortin (Ucn

78 Here we report the identification of corticotropin-releasing factor (CRF) as a critical compo

79 Exogenous corticotropin-releasing factor (CRF) but not corticoster

80 ng the endocrine arm of the stress response, corticotropin-releasing factor (CRF) can act in the brai

81 s-induced release of neuromodulators such as corticotropin-releasing factor (CRF) can drive drug-depe

82 To investigate corticotropin-releasing factor (CRF) contributions to fe

83 ses and how the stress-related neuropeptide, corticotropin-releasing factor (CRF) directs this by a b

84 regulation of the central extrahypothalamic corticotropin-releasing factor (CRF) expression is assoc

85 -term effects of an acute colitis on central corticotropin-releasing factor (CRF) expression.

86 The corticotropin-releasing factor (CRF) family of peptides

87 Urocortins are members of the corticotropin-releasing factor (CRF) family of peptides

88 Urocortin 3 (Ucn 3), a member of the corticotropin-releasing factor (CRF) family of peptides,

89 Peptides of the corticotropin-releasing factor (CRF) family signal throu

90 Urocortin 2 (Ucn 2), a member of the corticotropin-releasing factor (CRF) family, and its cog

91 Urocortin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with

92 hypersecretion of the stress neuromediator, corticotropin-releasing factor (CRF) has been implicated

93 rofiling of relevant PI cells identified the corticotropin-releasing factor (CRF) homolog, DH44, as a

94 ike ShA cocaine self-administration, reduced corticotropin-releasing factor (CRF) immunodensity in th

95 The role of amygdaloid corticotropin-releasing factor (CRF) in alcoholism is no

96 gates the regulation of cytosolic calcium by corticotropin-releasing factor (CRF) in midbrain dopamin

97 ed body of work indicates a crucial role for corticotropin-releasing factor (CRF) in neurobiological

98 vioral studies support a modulatory role for corticotropin-releasing factor (CRF) in regulating the d

99 termined the role of the stress neurohormone corticotropin-releasing factor (CRF) in stress-induced b

100 was used to study immunoreactivity (IR) for corticotropin-releasing factor (CRF) in the guinea pig e

101 ed on previous work hypothesizing a role for corticotropin-releasing factor (CRF) in the IC during cr

102 lores the relationship between dynorphin and corticotropin-releasing factor (CRF) in the induction of

103 halin (ENK)] with the stress-related peptide corticotropin-releasing factor (CRF) in the LC.

104 bout the distribution of the stress hormone, corticotropin-releasing factor (CRF) in the mouse brain.

105 We recently described the existence of corticotropin-releasing factor (CRF) in the mouse cochle

106 dies have found that the stress neurohormone corticotropin-releasing factor (CRF) inhibits 5-HT neuro

107 literature suggests that catecholamines and corticotropin-releasing factor (CRF) interact in a seria

108 Stress induces the release of the peptide corticotropin-releasing factor (CRF) into the ventral te

109 Corticotropin-releasing factor (CRF) is a key mediator o

110 Corticotropin-releasing factor (CRF) is also known as a

111 Corticotropin-releasing factor (CRF) is an important lin

112 The neuropeptide corticotropin-releasing factor (CRF) is believed to play

113 Corticotropin-releasing factor (CRF) is critical for the

114 Corticotropin-releasing factor (CRF) is expressed in the

115 ntial findings suggest that the neuropeptide corticotropin-releasing factor (CRF) is instrumental in

116 Corticotropin-releasing factor (CRF) is the major physio

117 The corticotropin-releasing factor (CRF) ligand family has d

118 Corticotropin-releasing factor (CRF) mediates anxiogenic

119 The present experiments examined whether corticotropin-releasing factor (CRF) modulates memory co

120 rning of day 15, we measured AT(1) receptors corticotropin-releasing factor (CRF) mRNA and immunoreac

121 Corticotropin-releasing factor (CRF) mRNA expression in

122 rsal mPFC enhanced restraint-induced Fos and corticotropin-releasing factor (CRF) mRNA expression in

123 re to elicit reliable increases in Fos-ir or corticotropin-releasing factor (CRF) mRNA in the PVH.

124 ysis of Fos induction and relative levels of corticotropin-releasing factor (CRF) mRNA.

125 and anxiety and activates a subpopulation of corticotropin-releasing factor (CRF) neurons in the bed

126 cohol intake specifically recruited GABA and corticotropin-releasing factor (CRF) neurons in the mPFC

127 Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should

128 the relationship between corticosterone and corticotropin-releasing factor (CRF) on both beta-amyloi

129 ed the effect of an intravenous injection of corticotropin-releasing factor (CRF) on fructose malabso

130 nced fear memory but did not increase either corticotropin-releasing factor (CRF) or corticosterone.

131 Injection of corticotropin-releasing factor (CRF) or urocortin III, k

132 Corticotropin-releasing factor (CRF) orchestrates the st

133 The corticotropin-releasing factor (CRF) peptide family is a

134 The corticotropin-releasing factor (CRF) peptide hormone fam

135 Because corticotropin-releasing factor (CRF) plays a role in str

136 Considerable evidence suggests that corticotropin-releasing factor (CRF) plays an important

137 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1)

138 duction and Abeta elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signalin

139 Corticotropin-releasing factor (CRF) receptor activation

140 The corticotropin-releasing factor (CRF) receptor CRFR2 is e

141 Corticotropin-releasing factor (CRF) receptor subtypes 1

142 The corticotropin-releasing factor (CRF) receptors (CRF1 and

143 Corticotropin-releasing factor (CRF) receptors are found

144 Because corticotropin-releasing factor (CRF) receptors are impli

145 Corticotropin-releasing factor (CRF) receptors have been

146 ife social isolation increases the levels of corticotropin-releasing factor (CRF) receptors in the se

147 Corticotropin-releasing factor (CRF) receptors-which bin

148 The stress-related neuropeptide, corticotropin-releasing factor (CRF) regulates the dorsa

149 induced relapse through alterations in brain corticotropin-releasing factor (CRF) regulation of neuro

150 Corticotropin-releasing factor (CRF) signaling at the CR

151 Alterations in corticotropin-releasing factor (CRF) signaling pathways

152 Activation of corticotropin-releasing factor (CRF) signaling pathways

153 Over the past few decades, corticotropin-releasing factor (CRF) signaling pathways

154 o negative reinforcement is a recruitment of corticotropin-releasing factor (CRF) signaling within th

155 Previous studies have implicated the brain corticotropin-releasing factor (CRF) stress systems in m

156 likely resulting from dysregulation of brain corticotropin-releasing factor (CRF) stress systems.

157 ment of the extrahypothalamic stress peptide corticotropin-releasing factor (CRF) system and activati

158 Dysregulation of the corticotropin-releasing factor (CRF) system has been imp

159 The corticotropin-releasing factor (CRF) system is the prima

160 ess systems, including the extrahypothalamic corticotropin-releasing factor (CRF) system, following l

161 The corticotropin-releasing factor (CRF) system, which is in

162 f neonatal amygdala (Neo-A) lesions on brain corticotropin-releasing factor (CRF) systems and hypotha

163 The corticotropin-releasing factor (CRF) type 1 receptor (CR

164 Systemic blockade of corticotropin-releasing factor (CRF) type 1 receptors (C

165 authors investigated the effect of blocking corticotropin-releasing factor (CRF) Type I and Type II

166 The authors investigated whether corticotropin-releasing factor (CRF) within the central

167 Corticotropin-releasing factor (CRF), a 41 amino acid pe

168 Here we report that corticotropin-releasing factor (CRF), a neuropeptide rel

169 The bimolecular interaction between corticotropin-releasing factor (CRF), a neuropeptide, an

170 -regulated by a major stress neuromodulator, corticotropin-releasing factor (CRF), acting on CRF type

171 The authors tested whether decreased corticotropin-releasing factor (CRF), an activator of fe

172 nsistent with this, the CEA highly expresses corticotropin-releasing factor (CRF), an important modul

173 ceruleus (LC)-norepinephrine (NE) neurons to corticotropin-releasing factor (CRF), an integral mediat

174 ays a role in the relationship among stress, corticotropin-releasing factor (CRF), and alcohol abuse.

175 he LC include excitatory amino acids (EAAs), corticotropin-releasing factor (CRF), and endogenous opi

176 (Dh44), a neuropeptide related to vertebrate corticotropin-releasing factor (CRF), and its receptor,

177 vitro and their modulation by dopamine (DA), corticotropin-releasing factor (CRF), and their combinat

178 The neuroactive substances corticotropin-releasing factor (CRF), arginine-vasopress

179 to the BNSTDL, is thought to communicate via corticotropin-releasing factor (CRF), but studies have y

180 The neuropeptide, corticotropin-releasing factor (CRF), coordinates the ph

181 Corticotropin-releasing factor (CRF), encoded by the CRH

182 -protein-coupled receptor B1 family includes corticotropin-releasing factor (CRF), growth hormone-rel

183 -adrenal (HPA) axis-activating neuropeptide, corticotropin-releasing factor (CRF), may be the keyston

184 ological studies indicate the involvement of corticotropin-releasing factor (CRF), noradrenaline, dop

185 Corticotropin-releasing factor (CRF), originally charact

186 Corticotropin-releasing factor (CRF), the major stress p

187 The focus is on the receptor for corticotropin-releasing factor (CRF), the orchestrator o

188 Corticotropin-releasing factor (CRF), the stress-related

189 Stress may impact on this system through corticotropin-releasing factor (CRF), which densely inne

190 ral amygdala noradrenergic substrates [via a corticotropin-releasing factor (CRF)-dependent mechanism

191 lacement regimens were tested for changes in corticotropin-releasing factor (CRF)-enhanced startle (i

192 allenge has been shown previously to cause a corticotropin-releasing factor (CRF)-mediated increase i

193 Corticotropin-releasing factor (CRF)-mediated mechanisms

194 Corticotropin-releasing factor (CRF)-related peptides ca

195 Corticotropin-releasing factor (CRF)-related peptides mo

196 Corticotropin-releasing factor (CRF)-related peptides se

197 agonists for the stress-related neurohormone corticotropin-releasing factor (CRF).

198 amygdala (CeA) that produce the neuropeptide corticotropin-releasing factor (CRF).

199 A major determinate of these responses is corticotropin-releasing factor (CRF).

200 n the lateral parabrachial nucleus coexpress corticotropin-releasing factor (CRF).

201 ntracerebroventricular infusion of saline or corticotropin-releasing factor (CRF).

202 action of the stress-associated neurohormone corticotropin-releasing factor (CRF).

203 nent of the stress response activated by the corticotropin-releasing factor (CRF).

204 d reward, including neuropeptide Y (NPY) and corticotropin-releasing factor (CRF).

205 vation of glucocorticoid receptors (GRs) and corticotropin-releasing factor (CRF).

206 ation of VTA dopaminergic neurons expressing corticotropin-releasing factor (CRF).

207 ) system by the stress-related neuropeptide, corticotropin-releasing factor (CRF).

208 two endogenous CRF-related peptide ligands, corticotropin-releasing factor [CRF rat/human (r/h)] and

209 known as maternal aggression) is impaired by corticotropin-releasing factor-(CRF) related peptides, b

210 ed neural cell density, stress neuropeptide (corticotropin releasing factor--CRF) levels, and plasma

211 This study tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK5616

212 ers of the corticoliberin family include the corticotropin releasing factors (CRFs), sauvagine, the u

213 rmones and is transcriptionally activated in corticotropin releasing factor-expressing cells.

214 ed with brain region-specific alterations of corticotropin-releasing factor expression and promoter m

215 The neuropeptides vasopressin and corticotropin-releasing factor facilitate, while seroton

216 oupled receptors, which bind peptides of the corticotropin releasing factor family and are key mediat

217 fashion both NGF and the hormone urotensin (corticotropin-releasing factor family ligand).

218 ortin 2, a recently identified member of the corticotropin-releasing factor family, is expressed in d

219 ivery of Urocortin I (UcnI), a member of the corticotropin-releasing factor family, suppresses feedin

220 ylglycines (NPPGs) as a novel class of human corticotropin releasing factor (h-CRF(1)) antagonists.

221 They further suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-ad

222 ephalin, thyrothropin-releasing hormone, and corticotropin-releasing factor immunoreactive cells in t

223 CRFR1) mediates the physiological actions of corticotropin-releasing factor in the anterior pituitary

224 doxical observations of increased release of corticotropin-releasing factor in the face of low cortis

225 tuitary-adrenal axis, including signaling by corticotropin-releasing factor, in the pathophysiology o

226 Corticotropin-releasing factor infusions into LA impair

227 Corticotropin-releasing factor infusions into the centra

228 Neuroendocrine hormones such as corticotropin-releasing factor, leptin and alpha-melanoc

229 in abnormal cerebrospinal fluid cortisol and corticotropin-releasing factor levels.

230 ated increments in restraint-induced Fos and corticotropin-releasing factor mRNA expression in the ne

231 w stress interacts with the neuromodulators, corticotropin-releasing factor, norepinephrine, dopamine

232 w explores the role of brain stress systems (corticotropin-releasing factor, norepinephrine, orexin [

233 s in the anterior hypothalamus that may gate corticotropin-releasing factor output from the amygdala

234 s an activation of the brain stress system's corticotropin-releasing factor outside of the hypothalam

235 in stress and appetite regulation, including corticotropin releasing factor, pro-opiomelanocortin B,

236 In our continued studies on corticotropin releasing factor receptor (CRFR1) signalin

237 The CRF system consists of two receptors, corticotropin releasing factor receptor 1 (CRF1R) and co

238 technique to a member of a class B GPCR, the corticotropin releasing factor receptor 1 (CRF1R).

239 opin releasing factor receptor 1 (CRF1R) and corticotropin releasing factor receptor 2 (CRF2R), a non

240 analysis showed significant upregulation of corticotropin releasing factor receptor 2 (CrfR2) in the

241 The current study examines the role of corticotropin releasing factor receptor subtypes 1 and 2

242 nvestigated here the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) a

243 tuted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) recep

244 methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) recep

245 cyclic imidazo[4,5-b]pyridin-2-ones as human corticotropin-releasing factor receptor (CRF(1)) antagon

246 ss, the physiological consequence of central corticotropin-releasing factor receptor (CRF-R) activati

247 viously reported differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 i

248 c disruption of signaling through the type 1 corticotropin-releasing factor receptor (CRFR1).

249 Administration of the selective corticotropin-releasing factor receptor 1 (CRF(1)) antag

250 In addition, we examined the role of the corticotropin-releasing factor receptor 1 (CRF(1)) in th

251 We aimed to characterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antag

252 noradrenergic (NE) receptors (alpha1) via a corticotropin-releasing factor receptor 1 (CRF-R1)-depen

253 rial evaluating the efficacy of GSK561679, a corticotropin-releasing factor receptor 1 (CRF1 receptor

254 We describe a novel corticotropin-releasing factor receptor 1 (CRF1) antagon

255 Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppres

256 Corticotropin-releasing factor receptor 1 (CRFR1) mediat

257 Similarly to what has been observed for the corticotropin-releasing factor receptor 1 (CRFR1), SAP97

258 me proliferator-activated receptor gamma and corticotropin-releasing factor receptor 1 were notable e

259 ecifically activated by either neurokinin I, corticotropin-releasing factor receptor 1, or dopamine D

260 Mice deficient in corticotropin-releasing factor receptor 2 (CRF2) (C57BL/

261 mutants with constitutive activation of the corticotropin-releasing factor receptor family homologue

262 d, we took the CRF(2(a))R and the homologous corticotropin-releasing factor receptor type 1 (CRF(1)R)

263 esent study investigated whether blockade of corticotropin-releasing factor receptor type 1 (CRF-R1)

264 n reflect reductions in anandamide driven by corticotropin-releasing factor receptor type 1 (CRF1) po

265 we investigated interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) w

266 Corticotropin-releasing factor receptor type 1 (CRFR1) i

267 ular membrane compartments, we show that the corticotropin-releasing factor receptor type 1 has a spe

268 ure of the transmembrane domain of the human corticotropin-releasing factor receptor type 1 in comple

269 The corticotropin-releasing factor receptor type 1 is a clas

270 here this equilibrium is established for the corticotropin-releasing factor receptor type 1.

271 Corticotropin-releasing factor receptor type 2 (CRFR2) h

272 vation of the central stress response, while corticotropin-releasing factor receptor type 2 (CRFR2) h

273 eviously, we observed abnormal expression of corticotropin-releasing factor receptor type 2 (CRFR2) t

274 The corticotropin-releasing factor receptor type 2a (CRF(2(a

275 ing affinity of 4-anilinopyrimidines against corticotropin-releasing factor receptor-1 (CRF(1)) (e.g.

276 Corticotropin-releasing factor receptor-1 (CRF(1)) media

277 n in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) anta

278 Effects on attention were attenuated by the corticotropin-releasing factor receptor-1 antagonist ant

279 NMR structure of the analogous domain of the corticotropin-releasing factor receptor.

280 Corticotropin-Releasing Factor Receptors (CRFRs) are cla

281 Corticotropin-releasing factor receptors (CRFRs), class

282 Alterations in central corticotropin-releasing factor signaling pathways have b

283 ry-adrenal axis), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intes

284 In addition, corticotropin-releasing factor systems were shown to fac

285 is function was probed using a dexamethasone/corticotropin-releasing factor test.

286 ess effect by counteracting the functions of corticotropin-releasing factor, the primary stress-media

287 peptides (ghrelin, nesfatin-1, somatostatin, corticotropin-releasing factor, thyrotropin-releasing ho

288 Corticotropin releasing factor type 1 (CRF1) is a key co

289 This hypothesis was investigated for the corticotropin-releasing factor type 1 (CRF(1)) receptor

290 A, alpha(1b) adrenergic (alpha(1b) ADR), and corticotropin-releasing factor type 1 (CRF-R1) and 2 (CR

291 hich oxytocin (OTR), vasopressin (V1aR), and corticotropin-releasing factor type 1 (CRF1) or type 2 r

292 Activation of corticotropin-releasing factor type 1 (CRF1) receptors i

293 icated that repeated social stress decreased corticotropin-releasing factor type 1 receptor and incre

294 We found that corticotropin-releasing factor type 1 receptor within th

295 disrupts this LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s)

296 disrupts this LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s)

297 re sensitive to central anorectic effects of corticotropin-releasing factor type 2 (CRF(2)) receptor

298 The corticotropin-releasing factor type 2 receptor (CRFR2) i

299 demonstrated that the mechanism involved the corticotropin-releasing factor type 2 receptor, cAMP ele

300 n the amygdala, which required activation of corticotropin-releasing factor type-1 (CRF-R1) receptors